Currently set to Index
Currently set to Follow

This week, the digital Novel Coronavirus Investment Forum (NCIF) offered a forward-looking analysis of the revolution in healthcare caused by the pandemic and the consequent exciting drive for innovation in the Life Sciences, HealthTech, and Digital sectors.

The virtual NCIF conference included over ten hours of high-level speeches and panel discussions. In addition, a global company showcased of 40+ presentations by corporates, offering innovative solutions and looking for capital and partnerships, among them ImmunoLogik and Proteona Antibody Protection, that will soon start funding campaigns on aecuvest.de.

Berlin-based ImmunoLogik is developing a novel antiviral agent with cellular targets, while Protenoa is developing a neutralizing antibody therapy against corona viruses.

The high-profile event with participants from all over the world and the aim to showcase early-stage innovation in healthcare was supported by EIT Health and Aescuvest.

Here you can listen and view, what top investors in health and life sciences had to say about the impact of the corona crisis on the sector:

Stay up to date on the latest investment opportunities and news at Aescuvest